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The section on anticancer gold complexes is based on the review paper: 
Dalton Trans. 2014, 43, 4209-4219 
 





1/ Metal ions in medicine 
 Metal ions are naturally present in biological systems. Indeed, metals such as iron, 
calcium, copper, zinc, magnesium, sodium or potassium are well-known essential elements 
of human body homeostasis. However, beyond these elements, many more are also present 
in traces. Thus, even though some of them are generally considered as toxic, metals such as 
selenium or molybdenum present benefic effects when present at very low concentrations.
1, 2
 
Moreover, not only the element or its amount inside the cell has to be considered in biology, 
but also the coordination environment of the metals is crucial to determine the balance 
between beneficial and toxic effects. As an example, “free” copper ions are almost absent in 
the cytosol and are highly toxic. Copper is carried through the cytoplasm by chaperons such 
as Atox1 and delivered to its actual destination such as mitochondria where it is incorporated 
into metalloenzymes. One example of such enzyme is cytochrome c oxidase which has a 
Fe/Cu center in its active site for the conversion of O2 to H2O.
3
 This highlights the 
importance of the coordination chemistry of metals in biological systems.  
Within this frame, coordination chemistry appears as a mandatory tool to describe 
the interactions of metal ions in cells, as well as to develop new drugs based on metal ions. 
The field of medicinal metal-based chemistry started at the beginning of the XX
th 
century 
with the use of the arsenic-based compound Salvarsan for the treatment of syphilis.
4
 Since 
then, this research area has been developed and metal-based compounds have appeared from 





 rheumatoid arthritis (gold)
7
 and cancer (platinum).
8
 Another important 
set of applications of metal complexes in medicine is their use for diagnosis purposes such as 
for example contrast agent in Magnetic Resonance Imaging (MRI) (gadolinium-, 
manganese- or iron-based complexes)
9, 10








A cartoon-picture of the current use of metal-based and 
inorganic compounds in the clinic is depicted in Figure 1.
13
  







Figure 1: Overview of the use of metal-based drugs in medicine. Reproduced from ref. 13. 
 
One of the main advantages of metal-based compounds is the high variability of possible 
structures and diversity of coordination geometries from linear two-coordinated, tetrahedral 




Figure 2: Examples of achievable geometries with metal-based compounds. 
 
This leads to extremely diverse structures. Thus, several research groups exploited metal 
centers to build up unprecedented 3D-architectures enabling increasing the selectivity toward 
selected biological targets.
14, 15, 16, 17  
 Moreover, the particular redox chemistry of transition 
metals opens also opportunities to design compounds with tuned redox properties in 
biological systems. This chapter will present the state of the art of anticancer metallodrugs 
from the most studied and used, the platinum-based compounds, to continue with the recent 
advances dealing with other transition metals such as ruthenium, iron, titanium, copper and 
gold. I will also discuss the strategy of using polymetallic complexes. In each case, I will 
present different representative examples and discuss their pharmacological effects and 
possible mechanisms of action. 





2/ Platinum-based anticancer drugs 
 
2.1/ Pt(II) complexes 
 
 Since the end of the 60’s and the discovery of the antiproliferative properties of the 
cis-diamminodichloridoplatinum(II) by Rosenberg
11
, platinum(II) compounds have been 
widely used in clinics as chemotherapeutic agents (fig. 3). Nowadays, among the thousands 
of platinum(II) compounds synthesized and screened for their anticancer properties, only 
three have been worldwide approved: Cisplatin, Carboplatin and Oxaliplatin, and other three 
have been approved at least in one country: Nedaplatin in Japan, Lobaplatin in China and 





Figure 3: Platinum compounds that reached market in at least one country. 
 
Cisplatin is widely used in treatment regimes in combination with different other drugs such 
as topoisomerase II inhibitors (doxorubicin, etoposide, mytomycin and epirubicin), mustards 
(cyclophosphamides, melphalan and ifosfamide), antimetabolites (gemcitabine, 5-
fluorouracil and methotrexate), vinca alkaloids (vinblastine and vinorelbine) and taxols 
(paclitaxel).
19 
It is currently applied to treat testicular cancer (for which the cure rate exceeds 
90 % and rises almost 100 % for the early-stage diseases), ovarian (although it tends to be 
replaced by Carboplatin), bladder, melanoma, non-small cell lung cancer (NSCLC), small 
cell lung cancer (SCLC), lymphomas and myelomas.
20, 21
 However, in spite of their great 
clinical success, platinum compounds present severe side effects including nephrotoxicity, 
emetogenesis and neurotoxicity that limit the doses administrated to patients. While some 
side effects can be managed by combining with other drugs, neurotoxicity remains a 
significant dose-limiting toxic effect. Moreover, both acquired and intrinsic mechanisms of 
resistance limit their spectrum of action.
22
 Understanding the cellular mechanism of 
Cisplatin-induced effects is thus a major goal in medicinal inorganic chemistry in order to 





rationally design new compounds that overcome resistance mechanisms and present 
decreased side effects.  
 Concerning the mechanisms of action, Cisplatin remains in its intact dichlorido 
form in the blood stream due to the high extracellular chloride concentration (100 mM). 





 will occur due to the lower chloride intracellular 
concentration (4-50 mM). These aqua species will then react with the biological targets.
23
 
DNA is recognized to be the main intracellular target of platinum-based drugs and Pt-nucleic 
acids interactions have been abundantly reviewed.
23, 24, 25, 26 
Platinum(II) compounds interact 
with DNA via the coordination of the cis-[Pt(NH3)2] fragment to the N
7
 atom of purine bases 
(guanine and adenine) by displacing the aqua ligands to form mainly 1,2- cis(GG) and 
cis(AG), 1,3-intrastrand cis(GNG) crosslinks or interstrand crosslinks.
23
 A cartoon-picture of 




Figure 4: Mechanisms of interaction of Cisplatin with DNA. Reproduced from ref. 23. 
 
Such crosslinks distort the structure of DNA duplex, notably by bending it significantly 
toward the major groove modifying the binding site of proteins. This bending can interfere 
with several transduction pathways including the p53 pathway, a protein responsible of 
induction of cell-cycle arrest or apoptosis in response to cellular stress and mutated in the 
majority of human tumors.
23
 Moreover, it has been shown that Cisplatin can induce G2-arrest 
leading to cell death.
23, 24
  
 Beyond the interactions of platinum-based compounds with DNA described in the 
previous section, the reaction of this class of metallodrugs with proteins has appeared 
fundamental for the understanding of the biological properties of platinum-based 
compounds.
27
 Indeed, interactions between proteins and platinum-based drugs are involved 
in numerous events including the regulation of metallodrug influx/efflux and detoxification.  





 The accumulation of Cisplatin is not completely understood and various 





ATPase, copper transporters (e.g. CTR1), and organic cation transporters (OCTs).
28
 A 
cartoon-picture summarizing Cisplatin’s tranporters is presented in Figure 5. 
 
 
Figure 5: Proposed influx/efflux mechanisms of Cisplatin. Reproduced from ref. 28. 
 
GSH and Atox1 are involved in the efflux mechanism of Cisplatin as well. Indeed, GSH, a 
tripeptide containing a cysteine residue, can coordinate heavy metals and transfer them to 
GS-X pumps eliminating GSH-conjugated species. That transporter family is known as 
multidrug resistance-associated proteins (MRPs) (fig. 5).
28 
Atox1 is a chaperon involved in 
copper homeostasis by transferring it to the copper efflux transporters ATP7A and ATP7B. 
The crystal structure of an adduct Atox1-Cisplatin has been solved suggesting its 
involvement in the mechanism of excretion of Cisplatin (fig. 5).
27, 28
 Metallothioneins (MTs) 
are a class of small proteins characterized by a high amount of cysteine residues (20 
cysteines in a 61-68 amino acid protein) responsible for the detoxification of heavy metals 
including platinum by sequestrating them (fig. 5). Such interactions lead to inactivation of 
the drugs inducing mechanisms of resistance toward platinum-based compounds.
27
 
Moreover, zinc-finger proteins have been identified as possible target of platinum-based 
drugs by displacement of the zinc cation by platinum. Within this frame, Cisplatin has been 
demonstrated to inhibit the zinc-finger protein poly(ADP-ribose) polymerase 1 (PARP-1) 
involved in the DNA repair mechanism.
29 





2.2/ Pt(IV) complexes 
 
Pt(IV) compounds present an octahedral geometry introducing two extra binding 
sites compared to Pt(II) complexes. Moreover, the kinetic inertness of Pt(IV) compounds 
toward reduction or ligand substitution makes them unlikely to react with biological 
nucleophiles. This increases their lifetime in blood and thus their chance to reach the tumor 
and enter the cells intact. It is hypothesized that the activity of Pt(IV) compounds follows the 
reduction of Pt(IV) to Pt(II) and the subsequent release of the two axial ligands leading to the 
biologically active Pt(II) species.  
 Within the various families of experimental Pt(IV) compounds developed so far, 
different drug design strategies were applied including: i) tuning the rate of reduction of the 
Pt(IV) center and the compound’s lipophilicity to optimize the release of Pt(II) drug into the 
cell
30
 and ii) making use of the two axial positions to couple Pt(II) moieties to bioactive 
ligands to allow “bifunctional” and targeted therapy.31  
Satraplatin, a trans-diacetato-cis-dichlorido Pt(IV) compounds with a 
cyclohexylamine ligand (fig. 6) has been shown to induce cell death in Cisplatin-resistant 
cell lines including human ovarian, lung and prostate cancer cell lines.
18, 30
 Satraplatin passed 
Phase I clinical trials in which myelosuppression and nausea appeared as dose limiting 
toxicities (DLTs). It reached Phase II clinical trial for the treatment of small-cells lung 
cancer and hormone refractory prostate cancer. It also gave interesting results in Phase III 
clinical trials in combination with prednisone on patients with refractory cancer (SPARC) 
reducing by 40 % the risk of cancer progression. However, it was rejected by the FDA due to 
lack of benefits in terms of overall survival. It is currently under Phase I, II and III clinical 
trials in combination with different drugs.
 
 
Some groups took advantage of the extracellular stability of the Pt(IV) metal center 
to build up targeted Cisplatin pro-drugs and “bifunctional” compounds bearing organic 
drugs. The main limitation of this approach is the intrinsic inertness of Pt(IV) complexes 
which renders the exchange of the axial ligands impossible and limitates the scope of ligands 
that can be introduced in these positions to the ones that can be incorporated during the 
oxidation step. Following this methodology, some trans-dihydroxido and trans-dichorido 
complexes were synthesized by oxidation with hydrogen peroxide or chlorine gas 
respectively.
32, 33
 Keppler et al. reacted the dihydroxido complex with succinic anhydride to 




 Dyson et al. developed a Cisplatin-based Pt(IV) complex incorporating two 
equivalents of ethacrynic acid (ethacraplatin, Fig. 6), a known inhibitor of the enzyme 
Glutathione-S-transferase which is supposed to be involved in the mechanism of resistance 
to Cisplatin. Indeed, ethacraplatin showed a faster toxicity against all tested Cisplatin-
resistant cell lines compared to Cisplatin alone.
35
   







Figure 6: Examples of Pt(IV) complexes under investigation. 
 
Lippard et al. developed a series of Pt(IV) complexes presenting different peptides for 
targeting αVβ3/αVβ5 integrins overexpressed in endothelial tumor cells.
35
 An example (Pt-
RGD) is presented in Figure 6. A recent work from Liu et al. reports the development of a 
fluorescent Pt(IV)-based targeted agent (TPS-DEVD-Pt-cRGD, Fig. 6).
37 In this compound 
cRGD moiety enables it to target cancer cells overexpressing integrin αvβ3 receptors. 
Moreover, the drug-induced apoptosis by in cellulo generated Cisplatin was detected 
monitoring the fluorescence of the tetraphenylsilole moiety (TPS) activated by caspase-3.  
 
3/ Ruthenium-based compounds 
 
 Ruthenium is studied as potential anticancer agent since the early 80’s following 
Clarke’s work who showed that the coordination complex fac-[(NH3)3RuCl3] presented an 
anticancer activity in murine models.
38
 In physiological environment, the most common 
oxidation states for ruthenium are +IV, +III and +II.
39
 In addition, ruthenium presents a 
relative kinetic inertness with ligand exchange time in the range of minutes to a few days 
(corresponding to ligand exchange kinetic of platinum) associated with affinity for sulfur-, 
nitrogen- and oxygen-donor containing ligands.
40
 As ruthenium belongs to the same column 
of transition metal as iron, it is isoelectronic to iron and can thus mimic its binding to 










3.1/ Ru(III) coordination complexes 
 
Among ruthenium-based compounds, coordination Ru(III) complexes are the only 
compounds to have reached clinical trials (fig. 7). Indeed, trans-[RuCl4(Im)(κ-S-
DMSO)][ImH] (NAMI-A) developed by Sava et al. and trans-[RuCl4(Ind)2] [IndH] 







Figure 7: Chemical structure of NAMI-A and KP1019. 
 
In spite of their high similarity, these two complexes present very different behavior 
in both in vitro and in vivo experiments: classically NAMI-A does not show cytotoxicity in 
vitro, whereas KP1019 shows marked antiproliferative activity against colorectal and colon 
carcinoma cell lines. Moreover, NAMI-A has been shown to act selectively against 
metastasis by inhibiting their proliferation and their development, when KP1019 has been 
proved to treat only primary tumors.
43
 Such differences of behavior is attributed to very 
different kinetics of aquation and reduction to Ru(II).
44
  
 Since the pioneering studies on Ru(III) complexes, Clarke proposed the hypothesis 
of “activation by reduction”, following the same principle as that of Pt(IV) derivatives, to 
explain the biological properties of such compounds: Ru(III) complexes are actually pro-
drugs that require to be reduced to the active Ru(II) species by intracellular reductants.
43, 45 
Due to their fast development and the lack of oxygen in the tumor environment, cancer cells 
overproduce energy via glycolysis resulting in an abnormally high level of lactic acid that 
creates a more reducing environment capable to convert Ru(III) into Ru(II).
 
However this 
hypothesis has never been proved up to now and its relevance to explain biological 
properties observed in vitro and in vivo remains under debate.
46
  
These complexes were originally designed following the instance of Cisplatin to 
interact with DNA but with the hope of a different mechanism of action to overcome 





Cisplatin resistance mechanisms. Brabeck et al. showed that ruthenium-based compounds 
can actually interact with DNA.
47
 In fact, although KP1019 may induce intrastrand adducts 
capable of stopping RNA synthesis in vitro, no real correlation between DNA binding and 
biological activity has been found yet. Conversely, for both NAMI-A and KP1019, it has 
been proved that their in vivo activity is due to interaction with other cellular components 
including proteins and enzymes. For example, NAMI-A’s antimetastatic activity would be 




 with intracellular 
proteases such as cathepsins
49
 when KP1019 has been shown to be able to interact with 
proteins, including serum proteins albumin and transferrin. Moreover it can induce apoptosis 






Based on the “activation by reduction” hypothesis suggesting that the actually 
effective species of ruthenium-based anticancer agent is at the +II oxidation state, several 
groups in the world started working on Ru(II)-based compounds which are active without the 
need of further reduction in a biological environment. Below we will present different 
families of Ru(II) complexes starting with the classical coordination compounds to continue 
with the organometallics. For each family I will focus on the most representative compounds 
and discuss their different mode of action. 
 
3.2.1/ Ru(II) polypyridyl complexes 
 
 Ru(II) polypyridyl complexes have been known to efficiently interact with DNA.
47
 
In 2000, Reedijk et al. reported three isomers of dichlorido-
bis(2-phenylazopyridine)ruthenium(II) complexes with very different anticancer activities in 
vitro: the α-[Ru(II)(azpy)2Cl2] (fig. 8) being almost ten times more efficient than Cisplatin.
51
 
This compound was shown to react with the nucleobase model 9-ethylguanine through 
coordination of the N
7
 on the Ru center.
52
 Analogues of this complex where the chlorides 
have been replaced by more stable toward hydrolysis dicarboxylate ligands showed a 
decreased activity but in any case no cross-resistance with Cisplatin or Carboplatin has been 
observed suggesting a different mode of action.
53
 The replacement of
 
the hydrolysable 
ligands by a third (N^N) chelating ligand of the bipy or azpy types resulted in the 
impossibility of direct binding between the metal center and DNA. Nonetheless, a reduced 
but still present anticancer activity was observed, suggesting that these compounds could 
trigger cell death through intercalative interaction with DNA.
54
 Moreover, Gust et al. 
demonstrated that Ru(II) tris-polypyridyl bearing an extended aromatic surface ligand 
4,5,9,16-tetraazadibenzo[a,c]naphtacene (fig. 8) with micromolar toxicity on cancer cells in 
vitro was active via a modification of the cell membrane function and cells adhesion 
properties.
55 






Figure 8: Chemical structures of two Ru(II) polypyridyl complexes with anticancer 
properties. 
 
In the last years, Ru(II) polypyridyl complexes presenting extended aromatic systems have 
been proved to selectively and efficiently interact and stabilize the unusual DNA structure G-
quadruplex.
56
 G-quadruplexes are peculiar nucleic acid architectures adopted by guanine-rich 
DNA and RNA sequences, and their stability originate in the stacking of contiguous G-
quartets (a planar and cyclic K
+
-promoted association of four guanines in a Hoogsteen 







Figure 9: Scheme of a guanine quartet stabilized by the presence of a potassium cation (left) 





Quadruplexes are currently intensively studied since they are suspected to play important 
roles in key cellular events: quadruplex-forming DNA sequences are indeed found in several 
pharmacologically relevant areas such as eukaryotic telomeres,
58
 promoter regions of 
identified oncogenes
59
 or promotor regions of HIV-1.
60
 Their stabilization by selective small 
molecules (also called G-quadruplex ligands)
61
 is thus currently investigated as a mean to 
control key cellular events (telomere homeostasis and, beyond this, chromosomal stability, as 





well as regulation of oncongenes expression, respectively). Moreover, accumulating 
evidence now points towards an increasing role of quadruplex ligands as DNA damaging 
agents.
62




 Finally it is worth mentioning that Ru(II) polypyridyl complexes possess interesting 
photophysical properties such as luminescence, photostability, as well as low metal to ligand 
charge transfer (MLCT) in the visible region avoiding the use of UV light and emission in 
the far-red region. Moreover, while MLCT-based luminescence is quenched in the free 
Ru(II) polypyridyl complexes, upon intercalation with DNA and overlapping of π systems 
between DNA bases an intense MLCT-based luminescence is displayed. That phenomenon 





3.2.2/ Organometallic (η6-arene)Ru(II) complexes 
 
 Tocher et al. showed in 1992 the ability of the organometallic moiety 
(η6-arene)Ru(II)Cl2 to enhance the cytotoxicity of the anticancer drug metronidazole 
[1-β-(hydroxyethyl)-2-methyl-5-nitroimidazole] (Fig. 10) upon coordination.65 Following 
these results, the field was largely explored by Dyson et al. They used the fragment [(η6-
arene)Ru(II)Cl2] coordinated by the water-soluble phosphane ligand PTA (PTA = 1,3,5-
triaza-7-phosphaadamantane) to give the so-called RAPTA complexes.
66
 The prototype 
RAPTA-C (arene = p-cymene) is depicted in Figure 10. Sadler et al. used ethylenediamine to 
chelate the fragment [(η6-arene)Ru(II)Cl]+ as in the case of the prototype compound RM175 




Figure 10: Chemical structure of pioneers (η6-arene)Ru(II) complexes.  
 
 The obtained results were the starting point of a very large library of compounds in 
which the arene,
68




 as well as the 
metal
71
 have been changed to try to draw a structure-activity relationship. Even though 





Dyson’s and Sadler’s compounds are very similar, both presenting the so-called “piano 
stool” geometry, they exert very different biological effects in vitro and in vivo.72 
 Indeed, RAPTA complexes show very low cytotoxicity in vitro against cancer cells 
but are highly active in vivo as antimetastatic agent being thus closer to NAMI-A in term of 
biological properties. RM175 is as efficient as Carboplatin (IC50 = 6 µM against A2780 
cells), and its analog, where the more lipophilic ligand tetrahydroanthracene replaces 
biphenyl, is as toxic as Cisplatin (IC50 = 0.6 µM against A2780 cells) in vitro. These results 
were confirmed in vivo as RM175 reduced growth of A2780 xenograft twice more than 
Cisplatin for tolerated doses.
73
 Moreover, it has been proved that these two types of 
arene-ruthenium compounds have different intracellular targets: the RAPTA family has been 
demonstrated to efficiently inhibit enzymes such as the cysteine protease cathepsin B, 
responsible for the degradation of the extracellular matrix, via interaction with Cys residues 
in the enzyme active sites.
74
 RM175 interacts preferentially with DNA via non-covalent 
hydrophobic bonds with the arene ligand,
52
 and through the substitution of the chloride 
ligand by N
7
 of guanine residues. 
 Interestingly, arene Ru(II) complexes (fig. 11) have also been reported to selectively 
inhibit cancer cells growth by arrest in S-phase through stabilization of a G-quadruplex 






Figure 11: Example of arene Ru(II) polypyridyl complex reported for anticancer properties 
via G-quadruplex stabilization. 
 
3.2.3/ Cyclometalated Ru(II) complexes 
 
 Another type of ruthenium(II) organometallic complexes designed for anticancer 
purposes are the cyclometalated compounds characterized by a covalent C-M (M = metal) 
bond and developed by Pfeffer et al. under the name RDC (Ruthenium Derived 
Compounds).
76
 Among the various compounds of this family, RDC11 (fig. 12) has shown 
particularly interesting antiproliferative properties in vitro in several cancer cell lines.
77
 
Moreover, it has been shown that this compound could block the cell cycle in G1 phase, a 
characteristic of cell death by apoptosis. RDCs induce apoptosis through activation of p53 





similarly to Cisplatin. However, it was demonstrated that for RDCs, the induction of 
apoptosis is only partially p53-dependent which, in association with the lower propensity of 
RDCs to excretion by ATP7B than Cisplatin, could suggests that RDCs induce apoptosis 
through a different pathway.
77
 Moreover, in vivo RDC11 has been shown to reduce tumor 
growth of B16F10 melanoma cells implanted in mice as efficiently as Cisplatin but with 






Figure 12: Chemical structure of the cycloruthenated complex RDC11. 
 
3.2.3/ “Structural” organometallic Ru(II) complexes 
 
 This class of compounds developed by Meggers et al. relies on a very different 
design strategy: while metal-based drugs are usually engineered for the metal center to 
directly interact with the biological target, for instance by replacement of hydrolysable 
ligands, in these compounds the ruthenium center is completely inert toward ligand 
substitution and is just present to build up 3D structures unreachable by classical carbon 
chemistry.
46
 As an example, compound DW1/2 (fig. 13) has been developed to mimic the 
natural product staurosporine, a potent inhibitor of protein kinases. This compound presents 
a metal-centered chirality and the S enantiomer (DW2) displays a better selectivity for one 
particular kinase, namely Pim-1 against which its efficacy is almost 100 times higher than 
staurosporine. Indeed this enantiomer mimics perfectly the interaction of the organic 
compound with the protein as shown by the crystal structure of Pim-1 with DW2.
79




Figure 13: Chemical structure of two enantiomers of the half-sandwitch complex DW1/2. 





 The racemic mixture (DW1/2), which is an inhibitor of GSK3β kinase, was tested 
against a panel of human melanoma cells overexpressing this protein and showed an activity 
in the low micromolar range against all tested cell lines. DW1/2 induces apoptosis on 
melanoma via intrinsic mitochondrial pathway while it is poorly toxic against normal 
melanocytes.
80
 It is worth mentioning that no interaction between the compound and DNA 
have been highlighted neither by coordination to nucleobases nor by intercalation into DNA 
duplex. This suggests that the anticancer activity of such compound is due to its ability to 
inhibit kinases and is thus independent to the direct involvement of the metallic center.
81 
 
4/ Iron-, titanium- and copper-based anticancer drugs 
 
4.1/ Iron-based complexes 
 
 Chemotherapeutic treatment of breast cancer mainly consists in administrating 
selective estrogen receptor modulators (SERMs) with Tamoxifen (fig. 14) being one of the 
most potent compounds in clinic. Thus, the coupling of a SERM to a metal-based scaffold 
appeared to be an interesting way to enlarge the scope of treatable cancers by metallodrugs. 
This concept was successfully applied by Jaouen, Vessières and coworkers who replaced the 
β-aromatic cycle in Tamoxifen, or in the analogue bearing an hydroxyl group in position 4 of 
the α aromatic cycle (hydroxytamoxifen), with a ferrocene moiety affording ferrocifen or 
OH-ferrocifen, respectively (fig. 14).
82
  
   
 
 










 It is worth mentioning that ferrocene belongs to the metallocene family in which the 
metal center is coordinated to two cyclopentadienyl ligands (Cp). In ferrocene, the iron 
center is in the +II oxidation state making ferrocene a neutral entity. Moreover, ferrocene 
attracted interest in medicinal chemistry due to its chemical stability, low toxicity, broad 
range of derivatization as well as interesting redox properties.
83
 
 In vitro, OH-ferrocifen appeared to inhibit the proliferation of the estrogen receptor-
positive cell line MCF-7 at 1 µM with the same efficiency as OH-tamoxifen. Moreover, 
upon addition of estradiol, an estrogen inducing proliferation of the estrogen receptor-
positive cells, OH-ferrocifen maintained certain toxicity. This finding suggests that 
ferrocifens trigger their toxic effects both by the estrogen receptor (ER) inhibitor capacity of 
the organic part and by intrinsic cytotoxicity of the organometallic moiety.
82 
This effect was 
confirmed in the screening of several cell lines, both ERα(+) and ERα(-). On ERα(+) cells, at 
a concentration of 0.1 µM, OH-ferrocifen presented an anti-hormone effect equivalent to 
OH-tamoxifen associated to a cytotoxic effect via accumulation of cells in S phase and ROS 
production. On ERα(-) cells, at a concentration of 1 µM, OH-ferrocifen still induced 
cytotoxicity while OH-tamoxifen appeared unefficient.
84 
  To further investigate structure-activity relationships, different ferrocene-based 
analogues of Tamoxifen were synthetized bearing several modifications in the lead scaffold: 
i.e. the hydroxyl group was removed, the ethyl chain was replaced by an aromatic ring, the 
conjugation between ferrocene and the aromatic ring was cut and a cyclopentadienyl ligand 
was substituted by methyl groups.
85
 These new derivatives were screened against hormone-
dependent (Tamoxifen-sensitive) and hormone-independent (Tamoxifen-resistant) breast 
cancer cell lines. It appeared that some of the tested compounds presented cytotoxic effects 
even on the hormone-independent cell lines. Conjugation between the ferrocene and the 
aromatic rings as well as the presence of the ethyl chain on the same carbon as the ferrocene 
moiety have been shown to be necessary for the development of cytotoxicity in cells.  
  From a mechanistic point of view, various studies confirmed that the oxidation of 
ferrocifens to quinone methide is the crucial step to drug activation (fig. 15). In fact, the 
quinone methide is believed to be the metabolite which will further interact with biological 











Figure 15: Mechanism of activation of ferrocifen in presence of a base and formation of 
quinone methide. Reproduced from Ref. 85. 
 
4.2/ Titanium-based complexes 
 
 Titanocene dichloride (fig. 16) is an organometallic Ti(IV) complex that was tested 
as a possible anticancer agent in the 80’s based on the fact that it presents two chlorido 
ligands in cis positions like Cisplatin.
86
 The compound appeared to be active in cancer cells 
both in vitro and in vivo on xenografted human gastrointestinal and lung carcinomas.
87
 
Titanocene dichloride reached phase I clinical trials where nephrotoxicity and increase of 
creatinine and bilirubin were noticed. In phase II clinical trial, it was found to be inefficient 
against metastatic renal-cell carcinoma.38 Titanium was shown to accumulate in nucleic acid 
rich areas where it acts by disrupting DNA synthesis, thus, highlighting DNA as a possible 
target in vivo.
88
  Moreover, Sadler et al. showed that titanium-based compounds could 
interact with the iron-transporter protein transferrin which internalizes iron from blood to the 
cells via an endocytosis mechanism. This interaction is proposed to be responsible of 
titanium uptake and release inside the cells.
89
 However, due to its very fast hydrolysis in 
physiological conditions, leading in fine to the insoluble TiO2 species, titanocene dichloride 
didn’t go further in the clinical trials even though some formulations to preserve the 
titanocene moiety were explored.
87, 88 







Figure 16: Chemical structure of titanium-based complexes that reached clinical trials. 
 
Another example of titanium-based compound which reached clinical trial is budotitane (cis-
[(EtO)2(bzac)2Ti] where bzac = 1-phenylbutane-1,3-diketonate) (fig. 16). This coordination 
compound showed interesting results in colorectal cancer in animal models.
87
 However, as 
for titanocene dichloride, hydrolysis of the metal-ligand bounds is the main limitation of 
budotitane. Some formulations of budotitane with glycerinepolyethylene-glycerolericinoleate 
and 1,3-propylene glycol yielded to an increased stability of budotitane in aqueous 
environment. However, the incapacity to well characterize the actually present species 
prevented budotitane to go further on drug development.
90
  
 Based on these results on titanocene dichloride, Tacke et al. developed different 
benzyl substituted titanocene analogues. One of them, the so-called titanocene Y bearing a 
4-methoxybenzyl substituent presented an IC50 value 100-fold lower than titanocene 
dichloride on pig kidney carcinoma cells.
91
 By replacing the two chlorido ligands by an 
oxalato ligand in titanocene Y (called oxali-titanocene Y), the same group succeeded in 
obtaining a 13-fold more toxic compound than titanocene Y on pig kidney carcinoma cells.
92
 
Moreover, oxali-titanocene Y also appeared almost 2-fold more toxic than Cisplatin on the 
same cell line. 
 
More recently, Tshuva et al. described the use of tetradentate bis(phenolato)ligands 
to increase the stability of cis-diisopropoxy titanium complexes toward hydrolysis. Those 
coordination compounds showed toxicity in the same range as Cisplatin on ovarian and 
colon cancer cell lines in vitro.
93
 Moreover, upon rigidification of the tetradentate ligand, 
Tshuva et al. synthetized trans-bisphenoxy titanium complexes with lower hydrolysis rate 






4.3/ Copper-based complexes 
 
 Copper is a human endogenous metal ion and an essential element for aerobic 
organisms as catalytic cofactor involved in many biological pathways.
1 
Aberrant levels of 
copper are linked with several pathologies such as Alzheimer’s or Parkinson’s diseases and 
Menkes’ syndrome.95 In the last years an increasing number of publications reported copper 
complexes, both in the +I and +II oxidation states, as efficient anticancer agents in vitro. 





These complexes presented a very broad range of ligands due to the extremely diverse 
coordination chemistry of copper. Among the various ligand types screened for Cu(II) 
complexes we can report S-donor containing ligands such as thiosemicarbazones or 
dithiocarbamates, acac-based ligands (acac = acetylacetonate), Schiff’s bases or bipyridine-
like chelators. Some representative examples are depicted in Figure 17.
95
  
 The coordination of N-heterocyclic carbenes to Cu(I) appeared to create highly 
potent compounds with 10 to 100-fold higher cytotoxicity compared to Cisplatin.
96
 While the 
majority of copper-based anticancer agents have been identified to interact with DNA upon 
intercalation or by cleavage of the strands upon generation of reactive oxygen species, some 
studies report copper compounds as efficient inhibitors of topoisomerase I and II and 
proteasome, thus extending the field of possible biological targets. Several compounds have 
been tested in vivo on Erlich ascites carcinoma, leukemia or breast cancer showing promising 






Figure 17: Examples of copper-based compounds studied as anticancer agents. 
  
5/ Gold-based anticancer drugs 
 
  Pharmacologic properties of gold are known since the end of 19
th
 century and gold 
compounds have been tested against different pathologies even though they are currently 
only used for the treatment of rheumatoid arthritis.
97
 However, besides the anticancer 
application of gold compounds I will describe, it is worth mentioning that gold complexes 
are currently investigated as possible antimicrobial agents.
98
 Gold presents a very broad 
spectrum of oxidation states from –I to +V, however, only the +I and +III oxidation states 
which are biologically relevant will be discussed below.
99
 Au(I) has a d
10
 electronic 
configuration and it gives compounds with linear geometry. Au(III) has a d
8
 electronic 
configuration and is thus isoelectronic to Pt(II) and presents a four coordinated square-planar 





environment that makes Au(III) complexes interesting candidates for anticancer evaluation. 
However, due to the fairly reducing intracellular milieu, the tendency of Au(III) center to get 
reduced to Au(I) makes the choice of ligands very determining.
100
 
 In this section, I will describe various families of gold compounds including Au(I) 
and Au(III) complexes. For each oxidation state, I will provide examples of coordination 
compounds (with phosphane or N-donor ligands) as well as organogold (compounds 
presenting a Au-C bound) and discuss their mechanisms of action.  
 
5.1/ Au(I) phosphane complexes 
 
 The first representative member of this family is Auranofin ((2,3,4,6-tetra-O-acetyl-
1-(thio-κS)--D-glucopyranosato)(triethylphosphane)gold(I)) (fig. 18), an orally 
administrated anti-arthritic agent, which has been reported by the end of the 70’s to inhibit 
cancer cells proliferation and DNA, RNA and proteins syntheses in vitro.
101
 In vivo, it has 
been shown to specifically increase the survival time of mice with P388 leukemia only when 
the treatment was given intraperitoneally.
102
 Based on these promising results, Auranofin and 
more generally speaking Au(I) compounds bearing phosphane ligands have been extensively 
studied and information on their chemical and biological properties have been reviewed on a 
regular basis.
86, 103, 104, 105 
 
 
Figure 18: Chemical structure of Auranofin. 
 
The intracellular mechanism of Auranofin has been extensively studied. Contrarily to 
Cisplatin, Auranofin is not reported to act by direct binding with DNA, but induces apoptosis 
via a mitochondria-related pathway.
101
 It was shown to be a highly potent and selective 
inhibitor of the seleno-enzymes thioredoxin reductases (TrxR), both cytosolic and 
mitochondrial, with an IC50 on the nanomolar range.
106
 Considering its overexpression in 
cancer cells, TrxR appeared as an interesting target for anticancer drugs. TrxRs as well as 
glutathione reductase (GR) are homodimeric enzymes whose role consists in reducing in a 
NADPH-dependent manner thioredoxin or glutathione, respectively. TrxR is responsible for 
the reduction of thioredoxin (Trx) which in turn reduces different proteins including 
ribonucleotide reductase (involved in conversion of ribonucleotide to desoxyribonucleotides 
for further synthesis of DNA) and peroxiredoxin (involved in the regulation of cellular level 
of hydrogen peroxide).
 107
 The thioredoxin system is depicted in Figure 19. 
 







Figure 19: Representation of the electron transfer pathway mediated by the TrxR/Trx 
system. 
 
Auranofin is supposed to interact preferentially with the selenocysteine residue of TrxRs 
considering the 1000-fold higher concentration required for the inhibition of glutathione 
reductase lacking the seleno-residue.
107 
This inhibition of the thioredoxin 
reductase/thioredoxin systems induces mitochondrial membrane permeabilization enabling 
the release of cytochrome c to the cytosol which triggers apoptosis.
108
 Moreover, inhibition 
of TrxR by Auranofin may allow overcoming the cross-resistance with Cisplatin in an 
ovarian cancer cell line in vitro.
109
  
 Beyond TrxR, Auranofin has been reported as potent inhibitor of the seleno-enzyme 
glutathione peroxidase responsible of the detoxification of hydrogen peroxyde
110 
and more 
recently as inhibitor of the sulfur-containing enzyme gluthatione-S-transferase which is 
suspected to be involved in the mechanism of resistance to Cisplatin.
111 
Structure-activity 
relationships studies on several Auranofin analogs, in which both the sugar and the 
phosphane ligands were varied, showed the great importance of the phosphane for the 
toxicity.
112
 Moreover, a mass-spectrometry study carried out on the reaction between 
Auranofin, Et3P-Au-Cl and cysteine or methylselenocysteine showed that, for both gold 





were formed, giving the opportunity to optimize Auranofin’s properties by replacing the 
thio-β-D-glucose tetraacetate moiety.113  
 Other studies on complexes of general formula R3P-Au(I)-Cl (R = alkyl or aryl) 
showed a positive correlation between the size of the substituents on the phosphorous atom 
and the cellular uptake and toxicity.
114
 Various targets have been investigated including TrxR 
but also other proteins/enzymes relevant to cancer. Ph3P-Au-Cl has been shown to efficiently 
inhibit in vitro cathepsin B, an enzyme belonging to the cysteine protease family implicated 
in inflammatory mechanisms.
115
 The development of gold(I)-phosphole chloride (GoPI) (1, 
fig. 20) and it’s thiosugar analogue (GoPI-sugar), the latter being more stable under 
physiological conditions, lead to highly efficient inhibitors of TrxR and GR accompanied by 
cytotoxic activities in the low micromolar range against glioblastoma or breast cancer cells 
in vitro.
116, 117 





Ott et al. associated the triethylphosphanegold(I) moiety with 
N-(N’,N’-dimethylaminoethyl)-1,8-naphtalimide ligand, an anticancer agent acting through 
DNA intercalation of the naphtalimide core and interaction of the protonable amino group 
with phosphate of the DNA backbone.
118, 119
 The resulting Au-Naphth-1 compound (2, fig. 
20) revealed to be as toxic as Et3P-Au-Cl in vitro, to inhibit TrxR to the same extent, but 
presented a higher uptake than Et3P-Au-Cl and antiangiogenesis properties the authors 
attributed to the presence of the naphtalimide moiety.
118, 119
  
Gimeno et al. reported the synthesis and the cytotoxic evaluation of Au(I) 
complexes bearing a diphenylphosphanoaminoheterocycle ligand associated to thiolate 
functionnalized pyridine or nucleic bases.
120
 The compound [Au(TG){PPh2NH(Htz)}] (TG = 
thioguanine) (3, fig. 20), appeared one order of magnitude more efficient than Auranofin 
against a cervical cancer cell line, whereas the reversed behavior was observed in case of a 
breast cancer cell line in vitro. Moreover, mechanistic studies demonstrated potent inhibition 
of TrxR (in the low or submicromolar range) associated with interactions with DNA. 
However, although the compounds interact with DNA, no structural change of DNA have 
been noticed which is in good agreement with the proposal of DNA not be being the main 




Figure 20: Examples of Au(I)-phosphane complexes investigated for anticancer properties. 
 
In vivo, a triphenylphosphane-gold(I) complex bearing an uracil-based ligand 
([Au(MANUH-1)PPh3]) (MANUH-1 = 6-amino-1-methyl-5-nitrosouracilato) (4, fig. 20) has 
been demonstrated to significantly reduce the growth of glioma tumor in mice. The treatment 
was associated with weak modification of serum parameters such as electrolytes, biomarkers 
of renal and hepatic functions and lipid profile, thus suggesting only very moderate side 
effects.
121 





 In the early stage of development of Au(I)-based anticancer agents, Berners-Price et 
al. reported the use of a delocalized lipophilic cation (DLC) based on bis-
(diarylylphosphano)ethane (5a-d, fig. 20). The tetrahedral 
bis-[bis(diphenylphosphano)ethane]gold(I) chloride (5a) has been shown to possess potent 
antitumor activity against a range of murine tumor model including leukemias, reticulum cell 
carcinoma, mammary adenocarcinoma and melanoma.
122
 However due to severe 
hepatotoxicity, the development of this compound didn’t go further.123 The authors attributed 
this lack of selectivity to the high lipophilicity of the compound resulting in a non-specific 
binding to intracellular components. They showed that the higher selectivity resulted of an 
average balance between lipophilicity and hydrophilicity. By plotting the antitumor 
properties in vitro vs the lipophilicity of the studied compounds, the authors found a 
maximum of the antitumor properties in vitro for the compound with average lipophilicity. 
Moreover, in vivo on mice with murine subcutaneous colon 38 tumors, the compound with 
intermediate lipophilicity presented the highest activity on tumor growth with a tumor 
growth delay of 9 days, pointing out the importance of fine tuning these parameters for the 
development of new drug candidates.
124
 Bis-[1,3-bis(dipyridylphosphano)propane]gold(I) 
chloride ([Au(d2pypp)2]Cl) (6 fig. 20) in which the spacer in between the two phosphanes is 
increased to give rise to 6-membered rings showed great selectivity for breast cancer cells 
compared to the healthy ones associated to an efficiency against malignant cells comparable 
to 5a. The compound, as DLCs in general,
125
 was shown to accumulate in mitochondria due 
to the negative mitochondrial membrane potential. Moreover, while the ethane-bridged 
compounds 5a-d showed only poor interactions with thiols, 6 can efficiently inhibit activity 
of both purified and cellular Trx and TrxR. The authors attributed this different behavior to a 
more labile phosphane ligand enabling the coordination of sulfur- or selenium-donor atoms 
to the gold center.
126 
 
5.2/ Au(III) complexes with chelating N-donor ligands 
 
  The gold(III) complexes [AuCl3(Hpm)] and [AuCl2(pm)] 
(Hpm = 2-pyridylmethanol) were tested against a panel of cancer cell lines in vitro and 
showed comparable activities to Cisplatin and NaAuCl4. The compounds were shown to 
interact closely with proteins such as albumin and transferrin but only weakly and reversibly 
with DNA. Although demonstrating the interest of gold(III) compounds, the substitution of 
the chlorido ligands by molecules of water at pH above 2 rendered them too instable in 
physiological environment for medicinal purposes.
127
 Thus, several polydentate ligands were 
tested to stabilize the gold(III) center, such as ethylenediamine (en), phenanthroline (phen) 
(19), 2-phenylazopyridine (azpy) (20), diethylenetriamine (dien) (21), terpyridine (terpy) 
(22) or macrocycles (TACN and cyclam) (23).
128, 129, 130
 Some of these complexes are 
depicted in Figure 21. The stability of some compounds was measured both by cyclic 
voltammetry and UV-Visible spectroscopy in the presence of reducing agents. It appeared 





that polyamine complexes were particularly stable, with the complex 23 presenting the 
highest stability toward reduction (table 1), although the most toxic compounds on ovarian 





Figure 21: Exemples of Au(III) complexes with N-donor ligands tested as anticancer agents.  
 
Table 1: Comparison between redox stability in aqueous solution at pH 7.4 and IC50 values 
on human ovarian cancer cells sensitive (A2780) and resistant to Cisplatin (A2780cisR) of 
some Au(III) complexes.  
Complex Ep (vs NHE
*
) (V) IC50 A2780 (µM) IC50 A2780cisR (µM) 
23
a - 0.20 99.0 > 120.0 
21
a + 0.19 8.2 ± 0.93 18.7 ± 2.16 
22
a + 0.62 0.2 0.37 ± 0.032 
19








* normal hydrogen electrode [a] data from ref. 128 [b] data from ref. 127 
 
The mechanism by which these compounds trigger their antiproliferative effect was carefully 
studied. Due to the isoelectronic structure of Au(III) cation compared to Pt(II), DNA was 
primarily envisaged as possible target. Even though it has been shown that Au(III) 
compounds can actually interact with nucleic acids through the coordination of their N-donor 







 the interaction calf thymus DNA appeared to be weak and reversible and could not 
explain the cytotoxic properties of this class of compounds.
132
  
  Some dimeric dioxido-bridged Au2 with bipyridine ligands have been developed by 
Cinellu et al. and are fairly stable at the +3 oxidation state under the dimeric form, with 
toxicities in the low micromolar range both against Cisplatin-sensitive and resistant ovarian 
cancer cell lines. The most cytotoxic one (24, fig. 21) has been demonstrated to tightly bind 
to calf thymus DNA. Indeed, inductively induced plasma optical emission spectroscopy 
(ICP-OES) measurements evidenced that more than 80 % of gold was still associated with 
DNA after ultrafiltration. Moreover, the reactivity of 24 with different proteins including 
human serum albumin (hSA), cytochrome c (cyt c) and bovine ubiquitin (Ubq) was 
investigated using spectrophotometric and mass spectrometry techniques. All experiments 
showed that 24 could react with protein through redox processes involving the breakdown of 
the dimeric structure as well as the release of the bipyridine ligand .
133
 
  Based on these results, the interactions with proteins appeared to be the main 
pathway by which such gold (III) complexes induce their toxic effects in cancer cells, 
explaining the low cross-resistance with Cisplatin.
134, 135
 Among the various enzymes 
screened as possible target of gold(III) metallodrugs, some revealed to be of particular 
interest. Indeed, gold(III) are very potent inhibitors of TrxRs and can induce mitochondrial 
swelling even though in a lower extent than Auranofin.
106
 More recent studies pointed out 
gold(III) as very powerful inhibitors of the zinc-finger enzyme PARP-1 compared to other 
metal-based drugs such as Ciplatin, NAMI-A or Auranofin in both purified enzyme and 
lysate.
29
 Using mass spectrometry techniques, 19 was demonstrated to displace zinc cation 
from the zinc-finger domain upon loss of all ligands including the phenanthroline. More 




  Finally, a unique family of Au(III) with N-donor ligands, is the Au(III) porphyrins' 
one, which is characterized by a very high stability upon reduction as assessed by cyclic 
voltammetry (Ep = -1.34 and -1.97 V vs NHE), but also in solution in the presence of cellular 
reductants such as glutathione. [Au(tpp)]
+
 (tpp = meso-tetraphenylporphyrin) (25, fig. 21) 
has been tested against a large panel of human cancer cell lines including Cisplatin- and 
multi-drug resistant cell lines with several hundred folds higher efficiency.
137
 In vivo data 
showed that 25 can reduce nasopharyngeal carcinoma tumor growth without body weight 
loss or liver injuries on mice. Mechanistic studies revealed that 25 triggers apoptosis through 





5.3/ Au(III) dithiocarbamate complexes 
 
  Gold(III) dithiocarbamate complexes developed by Fregona et al. are characterized 
by two symmetrical Au-S bounds giving rise to the stabilization of the +III oxidation state as 





assessed by cyclic voltammetry (5 mV ≤ Ep(Au-dithiocarbamate) ≤ 125 mV compared to Ep 




Figure 22: Chemical structures of the most studied dithiocarbamate-Au(III) complexes as 
anticancer agents. 
 
These compounds appeared highly toxic against a panel of human cancer cell lines including 
leukemia, cervical adenocarcinoma, colon adenocarcinoma or malignant melanoma in vitro. 
Moreover, comparison between toxicity on Cisplatin-sensitive and -resistant cell lines 
showed no cross-resistance with Cisplatin suggesting a different mechanism of action.
139
 
Furthermore, in vivo, [(DMDT)AuCl2] was proved to reduce prostate tumor xenografts in 
mice associated with good tolerance of the treatment.
140
 Such compounds trigger apoptosis 
through a different cellular target compared to other gold-based metallodrugs. Indeed, it has 
been shown that dithiocarbamate compounds act through the inhibition of proteasome both 




5.4/ Au(I) N-heterocyclic carbene (NHC) complexes 
 
  As previously mentioned, much effort has been directed towards the application of 
gold complexes for targeting mitochondrial cell death pathways. Following the successful 
application of gold phosphane complexes as antitumor agents, Berners-Price et al. have 
synthesized a variety of organometallic cationic mononuclear gold(I) biscarbene complexes 
as potential chemotherapeutic agents (7a-d fig. 23).
142, 143, 144
 The wingtip groups have been 
modified in order to adjust the lipophilic character of the complexes, a critical factor for 
targeting malignant cells. These gold organometallics display strong antimitochondrial 
effects, which can be attributed to both their cationic and lipophilic character. Very recently, 
a gold(I) biscarbene complex has been reported to decrease tumor size on mice bearing 
melanoma tumor without decreasing of body weight upon treatment.
145
 
   







Figure 23: Structures of biologically active gold(I)-NHC complexes.  
 
An important aspect of these organometallic complexes in regulating the biological activity 
is related to the presence of an ancillary ligand coordinated to gold, in addition to the Au-
NHC bond. Rubbiani et al synthesized three NHC gold(I) complexes of the 1,3-
benzimidazol-2-ylidene type (8a-c fig. 23) with different ligands (Cl, NHC, and PPh3, 
respectively).
146
 Initial DFT calculations revealed differences in bond dissociation energies 
(BDEs), which indicated an order of stability Cl < PPh3 < NHC. Experimentally, the 
complexes have different reactivity regarding binding to albumin and inhibition of the target 
enzyme TrxR. The chlorido derivative was a strong and selective inhibitor of TrxR and 
showed an intensive binding to albumin similar to Auranofin. The cationic biscarbene 
complex with two NHC ligands exhibited the lowest inhibition of TrxR and had 
concomitantly the lowest albumin binding capacity. Finally, the triphenylphosphane 
derivative 8b led to a strong inhibition of TrxR and also to an increased protein binding. 
Generally, TrxR was inhibited preferentially over structurally related enzymes (glutathione 
reductase GR and glutathione peroxidase GPx), and mass spectrometry studies with a 





selenocysteine-containing model peptide indicated that covalent interactions with selenium 
are highly relevant for the molecular mechanism of drug action. 
  The cellular uptake, as well as the biodistribution of the three complexes, were also 
studied by atomic absorption spectroscopy.
146
 Interestingly, the obtained results indicated 
that, for the derivatives 8a and 8b, which had the higher protein affinity, cellular gold levels 
in the presence of serum were decreased, suggesting that extracellular protein binding 
negatively influenced the compounds’ uptake. 
  With the purpose of achieving metal compounds imaging in biological 
environments, a gold(I)-NHC complex bearing a fluorescent anthracenyl ligand (9) was 
recently synthesized and the cytotoxic effects of the compound were investigated in vitro on 
different human cell lines of normal and cancer cells (fig. 23).
147
 The TrxR inhibition 
properties of this compound were also evaluated both directly on the purified enzyme and in 
cell extracts, comparing its ability to inhibit glutathione reductase, a pyridine-disulfide 
oxido-reductase maintaining glutathione in its reduced state. The effects of the new complex 
on the oxidation state of the thioredoxin system and peroxiredoxins were analysed.  
  In particular, considering mitochondrial peroxiredoxin 3 (Prx3), the redox state of 
the mitochondrial system after compound’s administration was highlighted.147 
Peroxiredoxins (Prxs) are enzymes decomposing peroxides using a highly reactive cysteine 
thiolate in their active site. Prx3 is kept reduced by the mitochondrial thioredoxin system, 
thus playing a role in protecting mitochondria from H2O2 produced by the respiratory chain 
complexes.
148
 Overall, the reported results indicate a correlation between the cytotoxicity of 
9 and Trx/Prx3 oxidation via TrxR inhibition in cells.
147
 Finally, fluorescence microscopy 
studies allowed visualizing the compound’s uptake and biodistribution in cells, showing a 
larger diffusion in tumor cells compared to normal ones (fig. 24). A very recent study using a 
gold(I)-NHC complex bearing a coumarin moiety showed the same bioditribution in human 
prostate cancer cells PC3.
149
  
  Other studies confirmed that many gold(I)-NHC complexes with the 1,3-substituted 
imidazole-2-ylidene and benzimidazol-2-ylidene ligands of type NHC-Au-L (L = Cl or 2-
mercapto-pyrimidine) (10, fig. 23) can potently inhibit both of the cytosolic and 
mitochondrial isoforms of the TrxR enzyme.
150
 The compounds showed marked and 
selective TrxR inhibition properties in particular in cancer cell lines. Remarkably, the most 
selective TrxR inhibitors induced extensive oxidation of thioredoxins (Trxs), which was 
more relevant in cancer cells (A2780) than in HEK-293T cells. Trx oxidation might be 
induced either by inhibition of TrxR by gold(I)-NHC complexes or by a massive increment 
of H2O2. However, the latter has not been detected at least in the A2780 and HEK-293T 
cells, at variance with what has been observed for other Au(I)-NHC complexes. 
 






a)                                b)                                 c) 
Figure 24: Visualization of the gold(I) NHC compound 9 using confocal microscopy in 
human embryonic kidney HEK-293T and human ovarian cancer Cisplatin resistant 
A2780cisR cells: a) fluorescence of the compound b) propidium iodide localization c) 
overlay. Images adapted from ref. 147. 
 
  In fact, it is worth mentioning that, among the several reported biologically active 
gold NHC complexes, distinct effects related to tumor cell proliferation inhibition have been 
described, including the increased formation of reactive oxygen species (ROS) or apoptosis 
induction.
151, 152, 153, 154
 However, it should be noted that a general direct correlation between 
TrxR inhibition and cytotoxic effects of gold NHC complexes could not so far always be 
claimed.
155
 This indicates that other mechanisms besides TrxR inhibition might contribute to 
their overall pharmacological profile. Very recently, Poly(ADP-ribose) polymerase 1 
(PARP-1), an enzyme which is involved into DNA repair mechanism
156
 and suspected to be 
involved into resistance to Cisplatin,
157
 has been demonstrated as a credible target for some 
Au(I)-NHC complexes.
158
 Moreover, some gold(I) N-heterocyclic carbene complexes have 
been proved to be efficient inhibitors of cysteine dependent protein tyrosine phosphatases 
(PTPs).
159
 PTPs are an enzyme family that plays important roles in various cellular processes 
and signaling pathways and that are considered targets for diseases including cancer or 
autoimmune disorders. 
  The possibility to synthesize compounds with a high degree of structural diversity is 
certainly among the features that make gold NHC complexes extremely attractive in drug 
design, as exemplified by recently reported complexes with hetero-biscarbenes or peptide 
bioconjugates.
160, 161, 162, 163, 164
 For example the peptide-Au-NHC compounds 11a-c (fig. 23) 
hold great promise due to their resistance overcoming in p53 deficient tumor cells.
163
 These 
complexes are also powerful inhibitors of TrxR, induce ROS formation and apoptosis, and 
trigger antimitochondrial effects. 





  The synthesis and cytotoxic properties of “bimodal” Au(I)-NHC complexes bearing 
a N,N-dimethyl-4,5-diarylimidazol-2-ylidene moiety, modeled on the naturally occurring 
vascular disrupting anticancer drug combretastatin A-4, have been recently reported (12a-d, 
fig. 23).
165
 Notably, in this work the transport mechanisms of a few compounds have been 
investigated showing that compounds’ uptake in 518A2 melanoma cells goes mainly via 
organic cation transporters (OCT-1/2) and copper transporters (Ctr1), similarly to Cisplatin. 
   
5.3/ Gold alkynyl complexes  
 Gold alkynyl complexes are a type of organometallics containing a gold(I) central 
atom with one or more coordinated alkynyl (R-C≡C-) ligands (see 13-18, fig. 25).166, 167 The 
alkynyl ligand is isoelectronic to cyanide (N≡C-) or carbon monoxide (CO) and can be 
interpreted as a pseudohalido ligand. Their most intensively studied property is 
luminescence, which was initially described in 1993 and is thought to be related to 
intraligand π-π* or Au-C σ-π* transitions.168 Despite the extended interest in these systems, 
biological properties related to metallodrug research are quite scarce.
169, 170, 171
 Of note, 
gold(I) alkynyl derivatives containing the water-soluble 1,3,5-triaza-7-phosphaadamantane 
(PTA) and 3,7-diacetyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane (DAPTA) phosphane 
ligands (see examples 13-14 in fig. 25) are cytotoxic in cancer cells and their cellular uptake 
was confirmed by fluorescence microscopy using the luminescent properties of these 
organometallics.
172
 As expected the complexes lack reactivity with DNA. Fluorescence 
microscopy also confirmed the cellular uptake of complexes containing fluorescent 
anthraquinone based ligands such as 15.
173
  
A recent study showed that mononuclear alkynyl gold complexes of the type 
alkynyl(triphenylphosphane)gold(I) (16, 17, fig. 25) exhibit a promising potential as future 
chemotherapeutics.
171
 In fact, these compounds were able to trigger antiproliferative effects 
and are strong inhibitors of TrxR with a high selectivity over the related enzyme glutathione 
reductase. Moreover, effects against tumor cell metabolism and mitochondrial respiration 
were observed, as well as significant anti-angiogenic properties in zebrafish embryos.  
 Finally, phosphane-bridged dinuclear gold(I) alkynyl complexes such as 18 are 
scarcely active against TrxR but still cause strong antiproliferative effects accompanied by 
an efficient cellular accumulation.
174  
   







Figure 25: Structures of cytotoxic gold(I) alkynyl complexes.  
 
5.6/ Cyclometalated Au(III) complexes with C,N-donor ligands 
 
 Cyclometallation reaction is the transition metal-mediated C-R bond activation of a 
wide range of organic molecules bearing donor atoms (D) such as N, O, P, S, and Se, and 
resulting in the formation of a chelate ring composed of a coordination D-M bond and a 
covalent M-C bond.
175
 Cyclometalated complexes are generally characterized by redox and 
thermodynamic stability. Moreover steric and electronic properties can be easily tuned by 
modification of either the anionic cyclometalated or the ancillary ligands to afford 
compounds with enhanced lipophilic character. 
  A variety of cyclometalated gold(III) complexes of nitrogen-donor ligands have 
been synthesized so far, featuring both bidentate C,N- and tridentate C,N,N-, C,N,C- and 
N,C,N-donor ligands (fig. 26), with either five- or six-membered C,N rings. Below are 
presented those that have been mostly studied for their anticancer properties and interactions 
with biological targets. 
 







Figure 26: General representation of cyclometalated gold(III) complexes with C,N-donor 
ligands (L = ancillary ligand). 
   
The discovery of the anti-tumor properties of the complex [Au(damp)Cl2],
176
 (damp = 2-
[(dimethylamino)methyl]phenyl), and its derivatives [(damp)AuX2] (X = SCN, OAc or X2 = 
oxalato, malonato)
177
 (26, fig. 27) by Parish and co-workers caused a renaissance of interest 
in gold(III) complexes as potential anticancer agents. These complexes displayed similar 
cytotoxicity to the one of Cisplatin against several human tumor cell lines, with the acetato 
and malonato complexes generally showing the best activities and selectivity in vitro, as well 
as moderate in vivo antitumor activity against human carcinoma xenografts.
176, 178 
Complex 
26 and its acetato and malonato analogues inhibit the cysteine proteases cathepsin B and K, 
with IC50 values of 0.6–1.36 μM and 1.3–3.3 μM, respectively,
179




   
 
 
Figure 27: Representative examples of cytotoxic cycloaurated complexes of the type 
[(C,N)Au(X,X)].  





 Following these promising results, a series of square planar six-membered 
cycloaurated complexes based on a pyridinyl-phenyl linked backbone (fig. 27) was found to 
inhibit the cysteine proteases cathepsin B and K, with IC50 values very similar to those found 
for the five-membered cycloaurated complexes.
181
 Five compounds of this series were 
evaluated for in vitro cytotoxicity against a panel of human tumor cell lines. In general, the 
leaving group had a pronounced effect on the cytotoxicity with the thiosalicylato compound 
being consistently more active than the chlorido compounds. Thus, the thiosalicylato 
compound was tested in vivo against the HT29 human colon tumor xenograft model, and a 
modest decrease in tumor growth was observed compared with the untreated control tumor. 
Various cyclometalated (C,N) gold(III) compounds, analogues of complex 26, with one, two 
or three carbon-gold bonds were evaluated in another study.
180
 In general, introduction of an 
increasing number of C-Au bonds makes the compounds more lipophilic, and thus facilitate 
intracellular uptake. However, the ability to interact with thiols or selenol groups of proteins 
appeared to be reduced. In addition, the damp derivative Au(damp)(C6H5)Cl, bearing two 
gold-carbon bonds, was found to be a potent inhibitor of TrxR (IC50 = 2.2 nM), nevertheless 
it is devoid of any anticancer activity against MCF-7 breast cancer and HT-29 colon cancer 
xenografts.
180
   
  The water-soluble biguanide complex [Au(R-C,N)(biguanide)]
+
 (R = 2-(4-n-
butylphenyl)pyridine, 27 fig. 27), which combines the lipophilic character imparted by the 
cyclometalated 2-(4-n-butylphenyl)pyridine with the hydrophilic properties given by the H-
bonding groups of the chelating biguanide, displays high toxicity against HeLa cells and low 
toxicity towards normal lung fibroblast CCD-19Lu cells.
182
 Complex 27 was found to react 
rapidly with GSH to form gold-GSH adduct(s); it induces endoplasmic reticulum (ER) stress 
and ER swelling, up-regulates ER-stress markers such as CHOP and HSP70, causes partial 
S-phase cell cycle arrest in HeLa cells following apoptosis- and necrosis-independent cell 
death. Moreover, 27 showed anti-angiogenic effects at sub-cytotoxic concentrations. 
  The biological activities of the cationic organogold(III) complex containing the 
“pincer” iminophosphorane ligand (2-C6H4-PPh2=NPh) (28 fig. 27) and its derivatives 
obtained from substitution of the chlorides with chelating ligands such as thiosalicylate, 
catecholate and dithiocarbamates, have recently been reported.
183, 184, 185
 The thiosalicylato 
and catecholato derivatives showed markedly higher anti-tumor activity versus P388 murine 
leukaemia cells compared to the parent chlorido complex.
183, 186 
The cationic 
dithiocarbamate-substituted complexes were highly active against HeLa human cervical 
carcinoma and Jurkat-T acute lymphoblastic leukaemia cells, and exhibited low toxicity 
against normal T-lymphocytes.
178, 179
 Mechanistic studies suggest that reactive oxygen 









 = 6-(1,1-dimethylbenzyl)-2,2’-bipyridine) (29 fig. 28), 
stable under pseudo-physiological conditions and cytotoxic towards different ovarian cancer 





cell lines sensitive and resistant to Cisplatin.
187
 In a more recent study, the compound was 
tested against a panel of 12 cell lines and showed moderate antiproliferative effects, as well 
as scarce selectivity. Interestingly, the analogue of 29 containing a 2,6-xylidine ligand (31) 
was markedly more cytotoxic and had a high degree of selectivity against a panel of 36 
human tumor cell lines. The obtained results were analyzed by COMPARE analysis and 
inhibition of mTOR, the proteasome, and/or DNA synthesis has been suggested as possible 
mechanism of action of such complex.
188
  
  The interaction of 29 with calf-thymus DNA has been proved to be weak and 
reversible, while the compound reacted with bovine serum albumin (BSA) most likely 
through coordination at the level of surface histidines.
189
 Further studies of the interaction of 
complex 29 with model proteins showed that small amounts of metal-protein adducts are 
also formed with cytochrome c and lysozyme, in which the gold(III) center and the C,N,N 
pincer ligand are conserved.
190
  
   
 
 
Figure 28: Representative mononuclear and dinuclear cyclometalated gold (C,N,N) 
complexes. 
 
Recently, 29 was reported to form stable adducts with the copper chaperone Atox-1 
containing gold in the oxidation state +1 as evidenced by high-resolution electrospray 
ionization mass spectrometry.
191
 However, it must be noted that, under the applied 
experimental conditions – i.e. the reducing environment provided by DTT – the gold(III) 
center may be pre-reduced to gold(I) with simultaneous loss of the starting ligands. Of note, 
Atox-1 is an intracellular metallochaperone crucially involved in copper trafficking, and the 
above mentioned studies may suggest that gold compounds are able to interfere importantly 
with the intracellular copper trafficking system also in vivo. 
  Studies of the effects of cyclometalated gold(III) compounds 29 and 31 showed that 
they inhibit mitochondrial TrxR2 and disrupt mitochondrial function triggering 
mitochondrial swelling, although the effects are reduced compared to Auranofin. These 









  In order to investigate metal binding to TrxR, MALDI-ToF MS experiments on the 
intact TrxR1 enzyme provided evidence for extensive enzyme metallation by 31, while 





 – bearing an attached gold(I) ion.193 Independent mechanistic 
information on the system was derived from BIAM (biotin-conjugate iodoacetamide) assays 
capable of monitoring selective metal binding to cysteine and/or seleno-cysteine residues. In 
this type of assay, while the effects produced by Auranofin, used as a reference TrxR 
inhibitor, could be essentially ascribed to gold(I) coordination to the active site selenol, the 
effects caused by the various gold(III) compounds were better interpreted in terms of 
oxidative protein damage. Overall, these results point towards the possibility of protein 
binding by (C,N,N) gold(III) compounds to other sites than Cys or Sec, such Met and His 
residues. 
  Interestingly, the cationic dinuclear oxido complexes [(N,N,C)2Au2(-O)][PF6]2 
(with N,N,CH = 6-(1,1-dimethylbenzyl)-2,2’-bipyridine (32) or 6-(1-methylbenzyl)-2,2’-
bipyridine (33)) (fig. 27) and their corresponding mononuclear hydroxido complexes were 
evaluated for cytotoxic actions against a representative panel of 12 human tumor cell lines. 
They showed moderate cytotoxicity towards the majority of them. Complex 33 was found to 
be particularly active against the human breast cancer 401NL cell line, while 32 showed 
poorly selective action. Most importantly, the dinuclear compounds appear to be very stable 
in the cellular environment, and possibly cause their still appreciable biological effects in the 
form of gold(III) species.
194
 As a matter of fact, mass spectrometry studies of 32-33 with 
model proteins evidenced that the resulting gold-protein adducts still contain gold ions in the 
oxidation state +3 and that the multidentate ligands are retained,
194
 at variance with what has 
been previously reported for other dinuclear and mononuclear gold(III) compounds bearing 
exclusively N-donor ligands.
133
 This also implies that the reactivity with proteins facilitates 
the cleavage of the oxygen bridge and the conversion of the bimetallic complexes into 
monometallic species. 
  Substitution reactions of the chlorido ligand in complex [Au(C,N,C)Cl] 34 
(HC,N,CH = 2,6-diphenylpyridine) afforded a series of cationic cycloaurated complexes, 
both mononuclear [Au(C,N,C)L]
+
 (L = 1-methylimidazole, 34a, pyridine, 34b, 
triphenylphosphane, 34c) and polynuclear [Aum(C,N,C)mL]
n+
 [L = imidazolate (n = +1), 
Ph2P(CH2)pPPh2, n = +2, m = 2, p = 1-6; L = Ph2P(CH2)2PPh(CH2)2PPh2, n = +2, m = 3) (fig. 
29).
195, 196
 The mononuclear compounds, containing non-toxic N-donor ancillary ligands, e.g. 
34a and 34b, were shown to exert anticancer potency comparable to that of Cisplatin, but 
they do not exhibit cross-resistance with Cisplatin against nasopharyngeal carcinoma, with 
resistance factors less than 1. Flow cytometry assays indicated that 34a causes cell death by 
apoptosis and cell-cycle analysis revealed S-phase cell arrest. Interestingly, further studies 
showed that 34a binds strongly by intercalation to calf-thymus DNA, and it also enhances 
G-quadruplex assembly, suggesting that it could act as an inhibitor of telomerase. Studies of 
human DNA topoisomerase inhibition indicated that 13a inhibits the topoisomerase I 





cleavage reaction since it prevents binding of the DNA substrate.
196 
  The dinuclear complexes (fig. 29) resulted to be in general much more active than 
their mononuclear counterparts, with IC50 values from 0.055 to 4.3 μM toward cancer 
cells.
196
 Their cytotoxicity correlates to that of the metal-free phosphane ligands (IC50 = 
0.13–38.0 μM), with [Au2(C,N,C)2(μ-dppp)]
2+
 35 and the free dppp (dppp = 1,3-
bis(diphenylphosphano)propane) being the most cytotoxic compounds in the series. Thus, 
the [Au(C,N,C)]
+
 moiety was regarded as a vehicle to carry highly cytotoxic phosphane 
ligands to cancer cells. Moreover, the gold phosphane complexes, although very cytotoxic, 
were found to interact only weakly with DNA and did not cause cell cycle arrest.
196 
  In vivo studies in rat bearing HCC orthografts showed that 35 causes significant 
inhibition in tumor growth (77% vs. vehicle control) and displays promising cytotoxicity 
towards cancer cells.
197
 Transcriptomic and connectivity map analyses have revealed that the 
transcriptional profile of this compound is similar to those of inhibitors of thioredoxin 
reductase and inducers of ER stress. Indeed, 35 is a nanomolar inhibitor of purified TrxR1, 
and effective in the micromolar range when TrxR activity assays are performed on cell 
extracts. Notably, the compound has also been subjected to acute and sub-chronic toxicity 
evaluation in nude mice and in beagle dogs. From these studies, no severe and irreversible 
side-effects were observed in association with the consumption of the compound at its 
effective concentrations in these animal models. Moreover, the gold complex does not 
induce noticeable genotoxicity as indicated by the analysis of micronucleus formation in rat 
bone marrow cells treated with it. 
 
 
Figure 29: Representative mononuclear and dinuclear cyclometalated gold (C,N,C) 
complexes. 
   
Replacing the phosphane by bridging carbene ligands (compounds 36, fig. 29) resulted in the 
reduction of the cytotoxic properties of the compounds, as well as lack of selectivity towards 
non-cancer cells. 
  A first example of supramolecular polymers self-assembled from cyclometalated 
gold(III) (C,N,C)-type complexes was recently reported with possible applications in 
medicinal chemistry. In this study, the mononuclear complex [Au(C,N,C)(4-dpt)]
+
 34d was 
synthesized, containing the anti-angiogenic ligand 2,4-diamino-6-(4-pyridyl)-1,3,5-triazine 





(4-dpt) able to form intermolecular hydrogen bonding and - interactions necessary to 
supramolecular complex formation.
198
 The compound was found to self-assemble into a 
supramolecular polymer when dissolved in MeCN at a concentration of 20 mM at 323 K and 
then cooled at 298 K.
198
  
  The gold-polymer was cytotoxic towards B16 cancer cells, and to a lesser extent 
towards non-tumorigenic lung fibroblasts CCD-19Lu cells, after a prolonged time. It is worth 
mentioning that, to avoid any direct contact of the supramolecular polymer with the cells, 
double chambered transwell 24-well plates containing a semipermeable membrane at the 
bottom of the upper chamber were employed in the cytotoxicity assay. The authors proposed 
that sustainable release of the free 4-dpt ligand and the concomitant formation of adducts of 
the gold compound with GSH may account for its cytotoxicity. Taken together, these results 
suggest that the gold-polymer could have potential application in sustained delivery therapy 
with improved therapeutic efficiency and safety by reducing the frequency of drug 
administration and the dose of drug required. For example, the gold-polymer could 
encapsulate the gold(III) porphyrin complex [Au(TPP)]Cl (H2TPP = meso-
tetraphenylporphyrin),
198
 thus providing the possibility to modulate its cytotoxicity in vivo 
and to reduce side toxicity through localized drug delivery. 
 
6/Multinuclear metal compounds 
 
 Beyond replacement of the platinum metal center by other transition metals, another 
strategy used to achieve improved drug design consists in increasing the number of metal 
centers into a molecular entity to enhance the anticancer properties of the compound. This 
concept is called multinuclearity. As for mononuclear species, compounds can be divided 
into coordination and organometallic polynuclear complexes and will be presented in this 
order in the following section. 
 The first polymetallic complexes synthetized and used for anticancer purposes were 
built based on the scaffold of Cisplatin (37 fig. 30).
199
 These compounds were shown to have 
a higher affinity for DNA than Cisplatin leading to the development of different derivatives 
in which the cis-trans configuration, as well as the overall charge were varied to optimize the 
biological properties.
200
 This led to the development of the trinuclear complex BBR3464 
(fig. 30) which displayed higher toxicity on sensitive cell lines in comparison to Cisplatin 
associated to an ability to overcome Cisplatin-resistance on several cancer cell lines. This 
compound reached Phase II clinical trial where it showed a lack of activity on gastric and 
small cell lung cancer preventing any further development.
18 
  Similarly, several ruthenium-based bimetallic complexes were developed on the 
basis of NAMI-A. An example of such compound is reported in Figure 30 (38). The 
bimetallic complexes revealed to have toxicity comparable with the parent compound 





NAMI-A. Moreover, these complexes could reduce both the number and the size of 






Figure 30: Examples of homopolynuclear coordination complexes studied as anticancer 
agents.  
 
Gold in oxidation states +I and +III was also studied for the synthesis of polynuclear 
compounds. Examples of homobimetallic coordination complexes have already been 
described in section 5 (24, fig. 24). Dinuclear Au(I) complexes bearing polyphosphane 
ligands (39, 40, fig. 30) appeared to be generally highly toxic both in vitro and in vivo on 
different murine tumor models.
200
 Compound 39 has been reported by Che et al. to induce 
autophagy, a process associated with cytotoxicity mechanisms and consisting in the 
sequestration of cytoplasmic components into autophagosome for further degradation by 
lysosomes.
202
 Other bimetallic gold(I) complexes based on the 2-arylimidazole scaffold 
(41a-b, fig. 30) were toxic in the low micromolar range against a panel of human cancer cell 
lines in vitro, with compound 41b being able to efficiently inhibit PARP-1 in a Cisplatin-









 Vilar et al. reported the synthesis and biological investigation of copper-based di- 
and trinuclear complexes (42-43, fig. 30).
 204
 42 has been shown to bind very efficiently to 
DNA with a 100-fold selectivity for G-quadruplex structures compared to duplex DNA 
structure. Complex 43 has also been reported of interacting with DNA, although with lower 
affinity than 42, mainly via groove binding mode. 43 has been demonstrated to have a highly 
potent nuclease activity associated to higher toxicity than Cisplatin against different cancer 
cells but also in the same extent against healthy cells.
205
 
 Reedijk et al. synthesized different heteropolynuclear complexes as DNA binding 
and cleavage agents. They developed complexes based on the Ru(terpy)2 moiety (terpy = 
2,2’:6’,2’’-terpyridine) coupled to [PtCl(terpy)] or [CuCl2(terpy)] moieties (44 and 45 fig. 




Figure 31: Examples of heteropolynuclear coordination complexes studied for interactions 
with DNA. 
 
44 was shown to form adduct with DNA base model 9-ethylguanine by coordination of the 
N
7
 to the platinum ion.
206
 45 and its analogues with higher numbers of metal centers 
appeared to be more efficient DNA cleavage agents than [CuCl2(terpy)].
207
 The authors 
attributed this increased potency to the presence of the inert ruthenium polypyridyl complex 
which favored the interaction with DNA via electrostatic interaction showing the possible 
associativity of the biological properties of each fragments. Another example of association 
of the properties of two metal-based fragments is presented in Figure 31 (46). Indeed, the 
Cisplatin-like fragment can preferentially bind on the GG DNA sequence placing the copper-
based nuclease agent in the close proximity of that sequence. Thus, this bimetallic Pt/Cu 
complex can cleave DNA selectively around GG sequences.
208
 
 Several polynuclear organometallic complexes have also been developed. Keppler 
et al. prepared a series of dimeric ruthenium-based complexes with different linker length 
(47, fig. 32). The authors noticed an increase in toxicity in vitro against a panel of human 





cancer cell lines including colon, ovarian, bladder, lung, breast, oesophagus and cervical 
cancer cells, following the increase of the size of the linker and the related compound’s 
lipophilicity.
209
 The compounds were shown to bind to transferrin but not to smaller proteins 
like ubiquitin or cytochrome c.  
 Interestingly, porphyrins were used to build up tetranuclear ruthenium complexes 
for possible “bimodal” applications in photodynamic therapy (PDT) and chemotherapy. 
Thus, for example using 5,10,15,20-tetra(4-pyridyl)porphyrin (4-tpp) as platform, the 
obtained tetrakis[(arene)RuCl] (48, fig. 32) showed moderate toxicity (IC50 = 50 μM for the 
most effective compound) against melanoma cells in vitro without irradiation.
210 
However, 
upon irradiation at 652 nm, even at low doses (5 J/cm
2
) photoactivation of the compound 





Figure 32: Examples of polynuclear organoruthenium complexes studied as anticancer 
agents. 
 
Different supramolecular organometallic cages have been developed by Suss-Fink et al. to 





Figure 33: Ruthenium-based organometallic cage. Reproduced from ref. 72.  





 While platinum or palladium acetylacetonato complexes are not toxic against 
ovarian cancer cells in vitro due to their high hydrophobicity, by being incorporated into the 
water-soluble cage both encapsulated platinum and palladium compounds (49, 50 
respectively) appeared more toxic than the empty cage. The palladium compound 50 
appeared 20-fold more efficient than the empty cage (IC50 = 1 μM and 23 μM respectively).
72
 
 In the previous chapter I already described the biological activity of different 
cyclometalated Au(III) complexes (compounds 32, 33 fig. 28 and 35, 36 fig. 29). Here I will 
focus on the dinuclear Au(I)-NHC complexes developed by Berners-Price et al. An example 




Figure 34: Example of bimetallic Au(I)-NHC complexes. Reproduced from ref. 212. 
 
52 was shown to induce mitochondrial swelling in isolated rat liver mitochondria, as well as 




 Moreover, it is 
worth mentioning that an analog of 52, where an ortho-xylyl bridge has been replaced by a 
propyl bridge resulting in a shorter Au-Au distance, was observed into mouse macrophage 




 Heterometallic polynuclear organometallic complexes have been developed based 
on ferrocene and titanocene dichloride scaffolds. Süss-Fink et al. synthesized di- and 
trinuclear Ru/Fe and Ru/Fe/Ru on the type of compounds 53 and 54 (fig. 35). While the 
dinuclear compounds appeared moderately toxic against ovarian cancer cells both Cisplatin-
sensitive and -resistant in vitro (IC50 ≈ 40 μM), the trinuclear complexes appeared twice 
more efficient than their dinuclear analogs on both cell lines. Moreover, the equivalent 
toxicities on both sensitive and resistant cells suggest a different mechanism of action 
compared to Cisplatin.
213
 Based on the ferrocene/mono- bisiminophosphorane platform 
Contel et al. developed polynuclear Au/Fe and Pd/Fe complexes (55 and 56 fig. 35). Both 55 
and 56 had been shown to have toxicity in the low micromolar range on all tested human cell 
lines including ovarian cancer (Cisplatin-sensitive and -resistant), breast cancer and healthy 
embryonic kidney cells for control. Both compounds appeared more toxic than their 
respective fragments. However, although both compounds have equivalent toxicities in vitro, 
they seemed to have different intracellular targets. Indeed 55 has been demonstrated to delay 





plasmid DNA on electrophoresis experiment indicating DNA as potential target while 56 





Figure 35: Examples of heteropolynuclear organometallic complexes studied anticancer 
purposes. 
 
Le Gendre et al. developed different titanocene dichloride-based polynuclear complexes 
associating titanium with ruthenium and gold moieties (compounds 57 and 58, respectively, 
Fig. 35). 57 revealed to be toxic in the low micromolar range against Cisplatin-sensitive and 
-resistant ovarian cancer cells in vitro (IC50 = 6.8 ± 1.3 μM and 4.5 ± 1.1 μM respectively) 
while both monometallic fragments: titanocene dichloride and RAPTA-C showed toxicities 
beyond 300 μM. Moreover, a mixture in a 1:1 ratio of these monometallic fragments gave 
toxicity beyond 200 μM evidencing the interest of polymetallic entities.215 Such behavior 
was also noticed in the case of the trinuclear complex 58 (IC50 = 0.40 ± 0.15 μM and 0.41 ± 
0.15 μM against sensitive and resistant ovarian cancer cells in vitro). It appeared also more 
toxic than the monometallic fragments, although in a lower extent due to the already high 
toxicity of the gold fragment. The higher measured toxicity for 58 was attributed to a higher 
intracellular uptake compared to its Ti/Au bimetallic analog as assessed by quantification of 




 Contel et al. developed Ti/Pd and Ti/Pt complexes (59 and 60 fig. 34). While the 
platinum compound 60 appeared not toxic against human cervical and prostate cancer cells 
in vitro, the palladium analog 59 revealed to be highly toxic against the cervical cancer cell 
line. Both compounds were shown to interact with CT-DNA via direct covalent bonds.
217
  





7/Aim and outline of the thesis 
 
 Within the field of Medicinal Inorganic Chemistry, the aim of this research project 
was the rational development of organometallic gold(I/III) complexes as possible anticancer 
agents. Thus, new series of gold compounds bearing N-heterocyclic carbene and (C,N) 
cyclometalated ligands were synthesized. The choice to focus on gold organometallics and 
not on coordination compounds was due to the fact that, in general, organometallic gold(I) 
and gold(III) complexes have higher stability compared to classical gold-based coordination 
complexes. Moreover, they are extremely suitable to design gold compounds acting as pro-
drugs, but in which the redox properties and ligand exchange reactions can be modulated to 
achieve selective activation in diseased cells. In addition, the possibility to couple more than 
one metal center in the same molecule to obtain dinuclear gold or even heteronuclear 
compounds was explored. 
 Initially, I focused on the synthesis of new Au(I)-NHCs scaffolds and on the 
identification of their possible biological targets. To achieve this aim, I tested the reactivity 
of my compounds towards different biomolecules including DNA and selected proteins. 
Some of the compounds were also designed to contain fluorescent ligands to facilitate the 
study of their uptake and sub-cellular distribution in cellulo. Thus, Chapter 2 focuses on the 
synthesis and chemical characterization of gold(I)-NHC complexes based on the natural 
product caffeine. Caffeine is a natural precursor for N-heterocyclic carbenes (NHCs) as it 
presents an imidazole ring, which is one of the most frequently used moieties for metal NHC 
synthesis. Moreover, caffeine and analogs has been recently reported as possible anticancer 
agents.
218
 Thus, I expected to obtain “bifunctional” compounds combining the properties of 
both Au(I)-NHC complexes with the intrinsic biological properties of the caffeine scaffold. 
One of the compounds revealed to be selective against human ovarian cancer cells in vitro. 
Notably, in that study I identified a new possible biological target for Au(I)-NHC complexes, 
namely DNA G-quadruplex structures. The most promising compound out of the in vitro 
screening was also tested in rat healthy organs using an ex vivo technique developed in Pr. 
Groothuis’s lab in Groningen. Specifically, I used the so-called Precision Cut Tissue Slices 
(PCTS) to evaluate compounds toxicity.
219
  
 In chapter 3 I pursued the synthesis of bimetallic complexes. Thus, I explored the 
synthesis of homo- and heterobimetallic complexes based on the Au(I) NHC scaffold, ideal 
for functionalization a posteriori. In detail, this chapter presents two different synthetic 
strategies to reach late/late type bimetallic complexes either by coupling two metal-based 
fragments or by incorporating a free ligand on the Au(I)-NHC scaffold enabling the selective 
coordination of a second metal. I could also extend the family of reachable compounds by 
replacing the chloride ligand on gold(I) by a thio-β-D glucose tetraacetate group .  
 In chapter 4, gold(I)-NHC complexes, incorporating a fluorescent moiety to follow 
their uptake and distribution inside the cells, were devloped. Two different types of sugar 





moieties (protected or not by acetate groups) were coupled to this scaffold to try to increase 
the uptake of the compounds possibly via GLUT-1 receptors. The various compounds were 
screened as possible inhibitors of the seleno-enzyme thioredoxin reductase (TrxR), a protein 
already reported as a target for gold-based metallodrugs (see Section 5), and promising 
results were obtained.
  
 In chapter 5, I explored the chemistry of (C,N) cyclometalated Au(III) complexes. 
Thus, I synthetized and fully characterized Au(III) complexes with different phosphane- or 
sulfur-based ancillary ligands. The photophysical properties of the compound bearing a 
fluorescent coumarin moiety were investigated. The compounds were tested in a panel of 
cancer cell lines, as well as in a model of healthy cells, showing certain selectivity.  
 In chapter 6, a new series of coordination Au(I) complexes, bearing ligands based 
on an organic drug, and synthesized in the lab of Prof. M. A. Cinellu (Dept. of Chemistry, 
University of Sassari, Italy) was screened for their antiproliferative properties in a series of 
cancer and non-tumorigenic cells. In detail, the gold(I) complexes contained the ligand 
lansoprazole, currently used as proton pump inhibitor (PPI) for the treatment of gastric and 
duodenum ulcers. This specific ligand has been chosen because it was shown that pre-
treatment with PPI increased uptake and efficacy of Cisplatin in tumors.
220
 Therefore, with 
these compounds we explored the possibility of increasing potency of Au(I)-based drugs by 
designing ’’bifunctional’’ anticancer agents. 
 Finally, the data obtained in this thesis are summarized and discussed in chapter 7. 
Moreover, future directions conserning the use gold-based compounds in anticancer 
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